12.18.00: Biotechnology Industry Issue
Eight leading analysts, one money manager, and top management from twenty-five sector firms examine the Biotechnology Industry in this special 145-page issue from The Wall Street Transcript.

    Online subscribers to the healthcare sector also get
    Medical Technology & Devices Issue & Outlook for E-health Companies Issue

  1. Biotechnology Industry - In an in-depth (14,800 words) Analyst Roundtable, Mark Augustine, Senior Research Analyst of Equity Research Group at U.S. Bancorp Piper Jaffray, Jeffrey Casdin, Chief Executive Officer at Cooper Hill Partners, LLC, Rachel Leheny, Senior Vice President at Lehman Brothers, examine the outlook for the sector, including reaching profitability, sources of capital, and share specific stock recommendations.
  2. Investing in Biotechnology - In an in-depth (13,200 words) Analyst Interview, Peter Drake, Managing Director of Equity Research, Charles Duncan, Senior Biotechnology Analyst, John Sonnier, Senior Biotechnology Analyst, and Robert Toth, Jr., Senior Analyst, all four at Prudential Vector Healthcare Group, examine the outlook for the sector, including differences between these companies and pure technology businesses, compares the impact of recent volatility on stocks from May of this year, and share specific stock recommendations.
  3. Outlook for Biotechnology Stocks - In an in-depth (3,000 words) Analyst Interview, William Slattery, Partner at Deerfield Management, examines the outlook for the sector, including the driving performance of the biotechnology stocks in 2000, industry trends, and shares specific stock recommendations.
  4. Money Manager Interview - B. Paul Abel, Senior Vice President of Kinetics Asset Management, examines portfolio management strategies in this timely and deeply informative 2,800-word interview from The Wall Street Transcript.
  5. The TWST confidential Off-The-Record survey of management performance at twenty-three sector firms asked market insiders about the ability of management teams to create shareholder value. Firms reviewed in Off-The-Record include:
    Abgenix, Alexion Pharmaceuticals, Alkermes, Amgen, Angiotech Pharmaceuticals, Applied Biosystems Group, Biogen, Cephalon, Corixa, CV Therapeutics, Gene Logic, Gilead Sciences, Gliatech, Guilford Pharmaceuticals, Human Genome Sciences, ICOS, Imclone Systems, Immunex, Medarex, Millennium Pharmaceuticals, Myriad Genetics, Teva Pharmaceutical Industries, Vertex Pharmaceuticals
  6. CEO interviews (average 2,500 words). Top management of twenty-five sector firms examine the outlook for their firm and the sector. Firms include:
    GalaGen, Inspire Pharmaceuticals, IOMED, Neurobiological Technologies, Photogen Technologies, TranXenoGen, VARIAGENICS, Ęterna Laboratories, Aquila Biopharmaceuticals, Axys Pharmaceuticals, Bio-Lok International, BioReliance, Corgenix Medical, Cytomedix, CRYO-CELL International, Endovasc, First Horizon Pharmaceutical, Lexicon Genetics, Matritech, NeoPharm, Pace Medical, Paracelsian, Pharsight, Repro-Med Systems, STGI
    7. ORDER THIS REPORT NOW! ONLY $175
    The report will be mailed first class. For fedex delivery, specify in the report details section and either include your fedex number or we will add $15 delivery charge. All sales are final.  Questions, call (212) 952-7433, or email us
    For immediate access online - click here to gain a password.
     
    Report details:  
    Your Name:  
    		 Company: 
    Address: 
    		 City: 
    State/Province:
    		 ZIP/Postal Code:
          		 Country:
    Phone:
    		 E-Mail:

    BILLING INFORMATION
    Credit Card
    		 Expiration Month/Year:
    Credit Card Number: 
     

     This Issue costs $175 - and is non-returnable.   

    The Wall Street Transcript does not endorse the views of any interviewee nor does it make stock recommendations.

     

Investors and Industry Execs.

The Wall Street Transcript has been used by investors and industry executives for 40 years as a unique tool for company and industry research.

TWST's roundtable panels and analyst interviews provide a sector perspective from Wall Street's best. 

Money manager interviews provide the view from the buy-side.

CEO interviews with hundreds of companies from the major sectors gives the company perspective right from the top.

Subscribe to a unique research tool for investors and industry executives. Call (212) 952 7433 or click here.

Sincerely,

Andrew Pickup
Publisher
HOME PRODUCTS SUBSCRIBE ABOUT ARCHIVE HOTLINE CONTACT EUROPE